Norwalk Virus Vaccine
Creative Biolabs is a world leader in the field of viral vaccine development. By consistently delivering the highest standards of quality, professionalism and integrity, we want to become the partner of a choice for your requirements. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services for Norwalk virus. We guarantee the finest results for our customers all over the world.
Norwalk virus (NoV) is a small round-structured virus that causes epidemic outbreaks of gastroenteritis worldwide, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, stomach flu, and winter vomiting disease. It is a single-stranded positive-sense RNA, non-enveloped virus and 27 to 32 nm in diameter belonging to the family Caliciviridae. It spreads primarily through the fecal-oral route and can have a big impact on people's health, directly from person to person and indirectly via contaminated water and food. NoV can also survive on surfaces that have been contaminated with the virus or be spread through contact with an infected person.
Virus-like Particle Vaccines
There are several virus-like particle (VLP) vaccine candidates under development to prevent acute viral gastroenteritis. A NoV VLP-rotavirus protein combination vaccine candidate consists of NoV capsid (VP1)-derived VLPs of GI-3 and GII-4 and rotavirus recombinant VP6 (rVP6), a conserved and abundant rotavirus protein. Components are expressed individually in the baculovirus expression system and then combined. In animal experiments, the vaccine showed strong and high-avidity NoV and rotavirus type-specific serum IgG responses and broad NoV-neutralizing activity of the sera.
Another NoV VLP vaccine which contained chitosan and monophosphoryl lipid A as adjuvants was under development to prevent acute viral gastroenteritis. This vaccine is a monovalent NoV VLP formulation delivered intranasally induced virus-specific serum antibodies in the majority of vaccine recipients. In summary, VLP vaccine with adjuvants provided homologous protection against both Norwalk virus-associated viral gastroenteritis and infection. This candidate can be used for a vaccination strategy to prevent norovirus disease.
A NoV P particle construct vaccine candidate is derived from the protruding (P) domain of the NoV VP1 capsid protein. P particles can be easily produced in E. coli expression systems at high yield and thus could represent a manufacturing advantage through relatively low cost of goods. When using a gnotobiotic pig model, the data showed the heterologous protective efficacy of the P particle vaccine was comparable to that of the VLP vaccine in pigs (60%) and the homologous protective efficacy in humans (47%).
Moreover, a novel vaccine which combined VLPs of norovirus GII.4 and enterovirus 71 (EV71, cause of hand, foot and mouth disease) was able to demonstrate functional antibodies to both viruses without evidence of interferences in a mouse study. Such a novel combination vaccine may offer additional value to areas of the world where both these diseases are prevalent. In short, these VLPs provide more possibilities for vaccine establishment against Norwalk virus.
Creative Biolabs is a highly proactive, robust and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against Norwalk virus. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
